My feeling is that Cytodyn is made up of amazing doctors...
My feeling is that Cytodyn is made up of amazing doctors... not the best businessmen. Regular PR's and presentations... are not good. Telling us the drug was safe when we already knew that was like telling us milk comes from cows. Tomorrow, we find out what we all want to know... HOW DOES IT WORK?
The science is there, and has been there, which is why we are here. Poor business makes the company look like amateurs and suseptible to short sellers... like AL and AF.
Trust the product, not the business. The product will drive the price as it is applicable to so many high need areas. Now is Covid, the biggest driver. Next will be HIV which is further ahead in the research and already a proven winner... Next is Cancer, GvH and NASH.
Having a company with issues makes it seem like it is a wonder drug being created by a company of idiots... enter ALand AF. The people running the company are NOT idiots, they are doctors. What would you rather? A business oriented company creating a drug or a doctor creating a drug? Ideally, we would be Pfizer or Gilead and have both. Have you seen Cytodyn's staff? They have .01% of the employees. They are stretched to wits end with what they are doing right now. Put the money in research now and when you get the money... get that business staff... make this a company that the FDA can't ignore because they already can't ignore the drug based on hardcore stats.
After Thursday after market, we can say see you shorts and thank you for keeping this stock as low as it was so that we could all buy more before the explosion in the pps.
I'm holding and hoping that the stats overcome the business and we can all retire early.
11
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
IQVentures Acquires Aaron's Company The acquisition landscape recently shifted with IQVentures Holdings, LLC, completing its purchase of Aaron's Company, Inc. (NYSE: AAN) in a landmark deal valued at approximately $504 million. This significant move culminates in a price of $10.10 per share, leading to the cessation of trading for Aaron's common stock on major exchanges....
Continue Reading
Vistra Boosts Shareholder Returns with Increased Dividends Vistra, a prominent player in the power generation and retail electricity sectors, has made headlines with its recent announcement regarding dividends. The company's board of directors has declared a quarterly dividend of $0.2260 per share for common stock holdings, amounting to a substantial total payout of...
Continue Reading
Hyperscale Data's Bitcoin Treasury Update Hyperscale Data, Inc. (NYSE American: GPUS), known for its innovative approaches to artificial intelligence and digital asset management, has reached a notable milestone. The company recently reported holding approximately 545.4218 Bitcoin, which is a significant increase compared to their previous estimates. This treasury is part...
Continue Reading
Overview of Clarivate's Q3 Financial Results Clarivate Plc (NYSE: CLVT), a noted global provider of transformative intelligence, has shared its financial results for the third quarter of the fiscal year. The company has seen continued acceleration in organic annual contract value (ACV) during this period. Significant Financial Highlights In this quarter, Clarivate's total...
Continue Reading
NexGold Celebrates a Key Milestone in Project Development NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF), a dedicated gold-focused mining company, has recently reached an important milestone by securing Industrial Approval (IA) for the Goldboro Gold Project. This approval comes from the Government of Nova Scotia and represents one of the final provincial permits needed...
Continue Reading